Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to welcome you to our first ever Learnings Call here at Recursion. So what is a learnings call and why are we ...
Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an ...
Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the ...
CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide ...
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback